Spots Global Cancer Trial Database for neratinib
Every month we try and update this database with for neratinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca | NCT03919292 | Solid Tumor, Ad... | Neratinib Divalproex Sodi... | 18 Years - | Virginia Commonwealth University | |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) | NCT04374305 | Neurofibromatos... Vestibular Schw... Non-vestibular ... Meningioma Ependymoma | Brigatinib Neratinib | 12 Years - | Massachusetts General Hospital | |
| Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer | NCT01423123 | Breast Cancer | Paclitaxel trastuzumab Neratinib | 18 Years - | NSABP Foundation Inc | |
| A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor | NCT01128842 | Advanced Malign... | Neratinib Capecitabine | 20 Years - | Puma Biotechnology, Inc. | |
| Treatment Patterns of Neratinib in HER2+ EBC in China | NCT05491057 | Breast Cancer | Neratinib | 18 Years - | Pierre Fabre Medicament | |
| Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | NCT01008150 | Breast Cancer | Paclitaxel Trastuzumab Neratinib Doxorubicin Cyclophosphamid... | 18 Years - | NSABP Foundation Inc | |
| Study Evaluating Safety And Tolerability, Solid Tumor | NCT00768469 | Advanced Malign... | Neratinib Paclitaxel | 20 Years - | Puma Biotechnology, Inc. | |
| A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | NCT02236000 | Breast Cancer | Neratinib T-DM1 | 18 Years - | NSABP Foundation Inc | |
| The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | NCT03182634 | Advanced Breast... | Fulvestrant Neratinib AZD5363 Olaparib AZD6738 | 18 Years - | Institute of Cancer Research, United Kingdom | |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | NCT01042379 | Breast Neoplasm... Breast Cancer Breast Tumors Angiosarcoma TNBC - Triple-N... HER2-positive B... HER2-negative B... Hormone Recepto... Hormone Recepto... Early-stage Bre... Locally Advance... | Standard Therap... AMG 386 with or... AMG 479 (Ganitu... MK-2206 with or... AMG 386 and Tra... T-DM1 and Pertu... Pertuzumab and ... Ganetespib ABT-888 Neratinib PLX3397 Pembrolizumab -... Talazoparib plu... Patritumab and ... Pembrolizumab -... SGN-LIV1A Durvalumab plus... SD-101 + Pembro... Tucatinib plus ... Cemiplimab Cemiplimab plus... Trilaciclib wit... SYD985 ([vic-]t... Oral Paclitaxel... Oral Paclitaxel... Amcenestrant Amcenestrant + ... Amcenestrant + ... ARX788 ARX788 + Cemipl... VV1 + Cemiplima... Datopotamab der... Datopotamab der... Zanidatamab Lasofoxifene Z-endoxifen ARV-471 ARV-471 + Letro... | 18 Years - | QuantumLeap Healthcare Collaborative | |
| Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | NCT00300781 | Breast Neoplasm... Neoplasms | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer | NCT01827267 | HER2-mutant Non... | neratinib temsirolimus | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | NCT00300781 | Breast Neoplasm... Neoplasms | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | NCT05388149 | Breast Cancer HER2-positive B... | Neratinib | 18 Years - | University Health Network, Toronto | |
| Study Evaluating HKI-272 in Tumors | NCT00146172 | Breast Neoplasm... | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | NCT02932280 | Solid Tumor Central Nervous... Lymphoma Leukemia | Neratinib | 3 Years - 21 Years | Memorial Sloan Kettering Cancer Center | |
| Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization) | NCT00708903 | Breast Cancer | neratinib Placebo Moxifloxacin | 18 Years - 50 Years | Puma Biotechnology, Inc. | |
| Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib | NCT05252988 | Early-stage Bre... HER2 Positive B... Hormone Recepto... | Neratinib Loperamide Colesevelam | 18 Years - | Spanish Breast Cancer Research Group | |
| Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | NCT03289039 | Breast Cancer | Neratinib Fulvestrant | 18 Years - | Dana-Farber Cancer Institute | |
| Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast | NCT03812393 | Triple Negative... Early-stage Bre... HER2-positive B... | Neratinib | 18 Years - | West Cancer Center | |
| Single Subject Neratinib in Bladder Cancer (NRR) | NCT01956253 | Bladder Cancer | Neratinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Personalized Medicine for Advanced Biliary Cancer Patients | NCT05615818 | Biliary Tract N... | Futibatinib Ivosidenib Zanidatamab Trastuzumab Neratinib Encorafenib Binimetinib Niraparib Cisplatin Gemcitabine | 18 Years - | UNICANCER | |
| A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | NCT00445458 | Advanced Breast... Advanced Malign... Breast Neoplasm... | HKI-272 Paclitaxel | 18 Years - | Puma Biotechnology, Inc. | |
| Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | NCT01111825 | Breast Cancer | Temsirolimus Neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | NCT02932280 | Solid Tumor Central Nervous... Lymphoma Leukemia | Neratinib | 3 Years - 21 Years | Memorial Sloan Kettering Cancer Center | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer | NCT04856475 | Breast Cancer Brain Metastase... | Neratinib | 18 Years - | Jules Bordet Institute | |
| Real-life Pan-HER-blockade With Neratinib | NCT04388384 | Breast Neoplasm | Neratinib | 18 Years - | Pierre Fabre Pharma GmbH | |
| Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | NCT03377387 | Breast Cancer | Capecitabine Neratinib EORTC QLQ - BR2... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer | NCT01670877 | Breast Neoplasm... | Neratinib Fulvestrant Trastuzumab Tumor biopsy Research blood ... | 18 Years - | Washington University School of Medicine | |
| Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | NCT01008150 | Breast Cancer | Paclitaxel Trastuzumab Neratinib Doxorubicin Cyclophosphamid... | 18 Years - | NSABP Foundation Inc | |
| Study Evaluating HKI-272 in Tumors | NCT00146172 | Breast Neoplasm... | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test | NCT05243641 | Metastatic Brea... Breast Cancer | Neratinib Capmatinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting | NCT01808573 | HER2+ Metastati... | neratinib capecitabine lapatinib | 18 Years - | Puma Biotechnology, Inc. | |
| Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT04781374 | Metastatic Pros... Castration-resi... Prostate Cancer Prostate Cancer... | Neratinib | 18 Years - | Beth Israel Deaconess Medical Center | |
| Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | NCT02673398 | HER2 Positive B... Stage IV Breast... | Comprehensive G... Laboratory Biom... Neratinib Pharmacological... | 60 Years - | City of Hope Medical Center | |
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | NCT05919108 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Invasive Breast... | Endocrine Thera... Biopsy of breas... Neratinib Biospecimen Col... Mammogram Magnetic Resona... Breast Surgery Ultrasound | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Fulvestrant + Neratinib In Breast Cancer | NCT04901299 | Stage IV (Metas... Metastatic Brea... ER Positive Bre... PR-Positive Bre... HER2-negative B... Invasive Breast... | NERATINIB FULVESTRANT | 18 Years - | Massachusetts General Hospital | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | NCT04886531 | Breast Cancer HER2-positive B... ER Positive Bre... PR-Positive Bre... | Neratinib Letrozole (L) o... Trastuzumab | 18 Years - | Hoosier Cancer Research Network | |
| Study Evaluating HKI-272 in Tumors | NCT00146172 | Breast Neoplasm... | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | NCT05388149 | Breast Cancer HER2-positive B... | Neratinib | 18 Years - | University Health Network, Toronto | |
| Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization) | NCT00708903 | Breast Cancer | neratinib Placebo Moxifloxacin | 18 Years - 50 Years | Puma Biotechnology, Inc. | |
| Study Evaluating HKI-272 Administered to Healthy Subjects | NCT00366600 | Healthy | neratinib | 18 Years - 50 Years | Puma Biotechnology, Inc. | |
| INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | NCT02977780 | Glioblastoma | Temozolomide Neratinib QBS10072S | 18 Years - | Dana-Farber Cancer Institute | |
| Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca | NCT03919292 | Solid Tumor, Ad... | Neratinib Divalproex Sodi... | 18 Years - | Virginia Commonwealth University | |
| A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer | NCT00398567 | Advanced Breast... | HKI-272 trastuzumab | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc | |
| Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | NCT03289039 | Breast Cancer | Neratinib Fulvestrant | 18 Years - | Dana-Farber Cancer Institute | |
| A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors | NCT00397046 | Tumors | neratinib | 20 Years - | Puma Biotechnology, Inc. | |
| A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors | NCT00397046 | Tumors | neratinib | 20 Years - | Puma Biotechnology, Inc. | |
| Treatment Patterns of Neratinib in HER2+ EBC in China | NCT05491057 | Breast Cancer | Neratinib | 18 Years - | Pierre Fabre Medicament | |
| A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib | NCT04366713 | HER2 Amplified ... | Neratinib Capecitabine Loperamide | 18 Years - | Puma Biotechnology, Inc. | |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | NCT03101748 | Breast Inflamma... Locally Advance... Metastatic Brea... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Cyclophosphamid... Doxorubicin Laboratory Biom... Neratinib Paclitaxel Pertuzumab Trastuzumab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | NCT02593708 | Solid Tumor | Neratinib Paclitaxel Pertuzumab Trastuzumab | 18 Years - | University of California, San Francisco | |
| Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | NCT00706030 | Breast Cancer Advanced Malign... | neratinib vinorelbine | 18 Years - | Puma Biotechnology, Inc. | |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc | |
| A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib | NCT04366713 | HER2 Amplified ... | Neratinib Capecitabine Loperamide | 18 Years - | Puma Biotechnology, Inc. | |
| Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | NCT01111825 | Breast Cancer | Temsirolimus Neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating Safety And Tolerability, Solid Tumor | NCT00768469 | Advanced Malign... | Neratinib Paclitaxel | 20 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating HKI-272 in Tumors | NCT00146172 | Breast Neoplasm... | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Real-life Pan-HER-blockade With Neratinib | NCT04388384 | Breast Neoplasm | Neratinib | 18 Years - | Pierre Fabre Pharma GmbH | |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) | NCT04374305 | Neurofibromatos... Vestibular Schw... Non-vestibular ... Meningioma Ependymoma | Brigatinib Neratinib | 12 Years - | Massachusetts General Hospital | |
| INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | NCT02977780 | Glioblastoma | Temozolomide Neratinib QBS10072S | 18 Years - | Dana-Farber Cancer Institute | |
| Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | NCT01953926 | Solid Tumors Ha... | Neratinib Fulvestrant Trastuzumab Paclitaxel | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer | NCT00266877 | Carcinoma, Non-... Lung Neoplasms | HKI-272 | 18 Years - | Puma Biotechnology, Inc. | |
| Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | NCT03377387 | Breast Cancer | Capecitabine Neratinib EORTC QLQ - BR2... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | NCT05919108 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Invasive Breast... | Endocrine Thera... Biopsy of breas... Neratinib Biospecimen Col... Mammogram Magnetic Resona... Breast Surgery Ultrasound | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ | NCT02593708 | Solid Tumor | Neratinib Paclitaxel Pertuzumab Trastuzumab | 18 Years - | University of California, San Francisco |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
